Expression of fibroblast growth factor 9 is associated with poor prognosis in patients with resected non-small cell lung cancer

Keiko Ohgino, Kenzo Soejima, Hiroyuki Yasuda, Yuichiro Hayashi, Junko Hamamoto, Katsuhiko Naoki, Daisuke Arai, Kota Ishioka, Takashi Sato, Hideki Terai, Shinnosuke Ikemura, Satoshi Yoda, Tetsuo Tani, Aoi Kuroda, Tomoko Betsuyaku

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Objectives: Fibroblast growth factor (FGF) 9 is a member of the FGF family, which modulates cell proliferation, differentiation, and motility. Recent studies show that the activation of FGF signals including FGF9 is associated with the pathogenesis of several cancers; however, its clinicopathological and biological significance in non-small cell lung cancer (NSCLC) is unclear. The purpose of this study was to clarify the characteristics of NSCLC with FGF9 expression. Materials and Methods: We evaluated the expression of FGF9 in resected NSCLC specimens and corresponding non-tumorous lung tissue samples using cDNA microarray and evaluated its clinicopathological characteristics. Results: Nine out of 90 NSCLC specimens (10%) had "high" FGF9 expression compared with corresponding non-cancerous lung tissues. Histologically, of the 9 NSCLC specimens with high FGF9 expression, 5 were adenocarcinoma, whereas none were squamous cell carcinoma. FGF9 expression was not associated with sex, smoking history, or clinical stage. However, in patients with high and low FGF9 expression, the postoperative recurrence rates were 78% and 24% (p= 0.033), respectively. Overall survival was significantly shorter in patients with high FGF9 expression than in those with low FGF9 expression (p<. 0.001). Conclusion: Our data indicate that FGF9 may be a novel unfavorable prognostic indicator and a candidate therapeutic target of NSCLC.

Original languageEnglish
Pages (from-to)90-96
Number of pages7
JournalLung Cancer
Volume83
Issue number1
DOIs
Publication statusPublished - 2014 Jan

Fingerprint

Fibroblast Growth Factor 9
Non-Small Cell Lung Carcinoma
Fibroblast Growth Factors
Lung
Oligonucleotide Array Sequence Analysis
Cell Movement
Cell Differentiation
Squamous Cell Carcinoma
Adenocarcinoma
Smoking
History
Cell Proliferation
Recurrence
Survival

Keywords

  • Adenocarcinoma
  • CDNA microarray
  • Fibroblast growth factor 9
  • Immunohistochemistry
  • Non-small cell lung cancer
  • Prognosis
  • Squamous cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Expression of fibroblast growth factor 9 is associated with poor prognosis in patients with resected non-small cell lung cancer. / Ohgino, Keiko; Soejima, Kenzo; Yasuda, Hiroyuki; Hayashi, Yuichiro; Hamamoto, Junko; Naoki, Katsuhiko; Arai, Daisuke; Ishioka, Kota; Sato, Takashi; Terai, Hideki; Ikemura, Shinnosuke; Yoda, Satoshi; Tani, Tetsuo; Kuroda, Aoi; Betsuyaku, Tomoko.

In: Lung Cancer, Vol. 83, No. 1, 01.2014, p. 90-96.

Research output: Contribution to journalArticle

Ohgino, K, Soejima, K, Yasuda, H, Hayashi, Y, Hamamoto, J, Naoki, K, Arai, D, Ishioka, K, Sato, T, Terai, H, Ikemura, S, Yoda, S, Tani, T, Kuroda, A & Betsuyaku, T 2014, 'Expression of fibroblast growth factor 9 is associated with poor prognosis in patients with resected non-small cell lung cancer', Lung Cancer, vol. 83, no. 1, pp. 90-96. https://doi.org/10.1016/j.lungcan.2013.10.016
Ohgino, Keiko ; Soejima, Kenzo ; Yasuda, Hiroyuki ; Hayashi, Yuichiro ; Hamamoto, Junko ; Naoki, Katsuhiko ; Arai, Daisuke ; Ishioka, Kota ; Sato, Takashi ; Terai, Hideki ; Ikemura, Shinnosuke ; Yoda, Satoshi ; Tani, Tetsuo ; Kuroda, Aoi ; Betsuyaku, Tomoko. / Expression of fibroblast growth factor 9 is associated with poor prognosis in patients with resected non-small cell lung cancer. In: Lung Cancer. 2014 ; Vol. 83, No. 1. pp. 90-96.
@article{3e82bd6ef715452a8e24ade54bb6b5ca,
title = "Expression of fibroblast growth factor 9 is associated with poor prognosis in patients with resected non-small cell lung cancer",
abstract = "Objectives: Fibroblast growth factor (FGF) 9 is a member of the FGF family, which modulates cell proliferation, differentiation, and motility. Recent studies show that the activation of FGF signals including FGF9 is associated with the pathogenesis of several cancers; however, its clinicopathological and biological significance in non-small cell lung cancer (NSCLC) is unclear. The purpose of this study was to clarify the characteristics of NSCLC with FGF9 expression. Materials and Methods: We evaluated the expression of FGF9 in resected NSCLC specimens and corresponding non-tumorous lung tissue samples using cDNA microarray and evaluated its clinicopathological characteristics. Results: Nine out of 90 NSCLC specimens (10{\%}) had {"}high{"} FGF9 expression compared with corresponding non-cancerous lung tissues. Histologically, of the 9 NSCLC specimens with high FGF9 expression, 5 were adenocarcinoma, whereas none were squamous cell carcinoma. FGF9 expression was not associated with sex, smoking history, or clinical stage. However, in patients with high and low FGF9 expression, the postoperative recurrence rates were 78{\%} and 24{\%} (p= 0.033), respectively. Overall survival was significantly shorter in patients with high FGF9 expression than in those with low FGF9 expression (p<. 0.001). Conclusion: Our data indicate that FGF9 may be a novel unfavorable prognostic indicator and a candidate therapeutic target of NSCLC.",
keywords = "Adenocarcinoma, CDNA microarray, Fibroblast growth factor 9, Immunohistochemistry, Non-small cell lung cancer, Prognosis, Squamous cell carcinoma",
author = "Keiko Ohgino and Kenzo Soejima and Hiroyuki Yasuda and Yuichiro Hayashi and Junko Hamamoto and Katsuhiko Naoki and Daisuke Arai and Kota Ishioka and Takashi Sato and Hideki Terai and Shinnosuke Ikemura and Satoshi Yoda and Tetsuo Tani and Aoi Kuroda and Tomoko Betsuyaku",
year = "2014",
month = "1",
doi = "10.1016/j.lungcan.2013.10.016",
language = "English",
volume = "83",
pages = "90--96",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Expression of fibroblast growth factor 9 is associated with poor prognosis in patients with resected non-small cell lung cancer

AU - Ohgino, Keiko

AU - Soejima, Kenzo

AU - Yasuda, Hiroyuki

AU - Hayashi, Yuichiro

AU - Hamamoto, Junko

AU - Naoki, Katsuhiko

AU - Arai, Daisuke

AU - Ishioka, Kota

AU - Sato, Takashi

AU - Terai, Hideki

AU - Ikemura, Shinnosuke

AU - Yoda, Satoshi

AU - Tani, Tetsuo

AU - Kuroda, Aoi

AU - Betsuyaku, Tomoko

PY - 2014/1

Y1 - 2014/1

N2 - Objectives: Fibroblast growth factor (FGF) 9 is a member of the FGF family, which modulates cell proliferation, differentiation, and motility. Recent studies show that the activation of FGF signals including FGF9 is associated with the pathogenesis of several cancers; however, its clinicopathological and biological significance in non-small cell lung cancer (NSCLC) is unclear. The purpose of this study was to clarify the characteristics of NSCLC with FGF9 expression. Materials and Methods: We evaluated the expression of FGF9 in resected NSCLC specimens and corresponding non-tumorous lung tissue samples using cDNA microarray and evaluated its clinicopathological characteristics. Results: Nine out of 90 NSCLC specimens (10%) had "high" FGF9 expression compared with corresponding non-cancerous lung tissues. Histologically, of the 9 NSCLC specimens with high FGF9 expression, 5 were adenocarcinoma, whereas none were squamous cell carcinoma. FGF9 expression was not associated with sex, smoking history, or clinical stage. However, in patients with high and low FGF9 expression, the postoperative recurrence rates were 78% and 24% (p= 0.033), respectively. Overall survival was significantly shorter in patients with high FGF9 expression than in those with low FGF9 expression (p<. 0.001). Conclusion: Our data indicate that FGF9 may be a novel unfavorable prognostic indicator and a candidate therapeutic target of NSCLC.

AB - Objectives: Fibroblast growth factor (FGF) 9 is a member of the FGF family, which modulates cell proliferation, differentiation, and motility. Recent studies show that the activation of FGF signals including FGF9 is associated with the pathogenesis of several cancers; however, its clinicopathological and biological significance in non-small cell lung cancer (NSCLC) is unclear. The purpose of this study was to clarify the characteristics of NSCLC with FGF9 expression. Materials and Methods: We evaluated the expression of FGF9 in resected NSCLC specimens and corresponding non-tumorous lung tissue samples using cDNA microarray and evaluated its clinicopathological characteristics. Results: Nine out of 90 NSCLC specimens (10%) had "high" FGF9 expression compared with corresponding non-cancerous lung tissues. Histologically, of the 9 NSCLC specimens with high FGF9 expression, 5 were adenocarcinoma, whereas none were squamous cell carcinoma. FGF9 expression was not associated with sex, smoking history, or clinical stage. However, in patients with high and low FGF9 expression, the postoperative recurrence rates were 78% and 24% (p= 0.033), respectively. Overall survival was significantly shorter in patients with high FGF9 expression than in those with low FGF9 expression (p<. 0.001). Conclusion: Our data indicate that FGF9 may be a novel unfavorable prognostic indicator and a candidate therapeutic target of NSCLC.

KW - Adenocarcinoma

KW - CDNA microarray

KW - Fibroblast growth factor 9

KW - Immunohistochemistry

KW - Non-small cell lung cancer

KW - Prognosis

KW - Squamous cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84891744568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891744568&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2013.10.016

DO - 10.1016/j.lungcan.2013.10.016

M3 - Article

VL - 83

SP - 90

EP - 96

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 1

ER -